161 related articles for article (PubMed ID: 37414632)
21. Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease.
Zhao LP; Schell B; Sébert M; Kim R; Lemaire P; Boy M; Mathis S; Larcher L; Chauvel C; Dhouaieb MB; Bisio V; Preudhomme C; Marceau-Renaut A; Itzykson R; Mekinian A; Fain O; Toubert A; Fenaux P; Dulphy N; Clappier E; Adès L
Leukemia; 2021 Sep; 35(9):2731-2733. PubMed ID: 34344988
[No Abstract] [Full Text] [Related]
22. Intractable pruritus in chronic myelomonocytic leukaemia and myelodysplastic syndromes: a case series.
Ceesay MM; Basu TN; du Vivier A; Mufti GJ
BMJ Case Rep; 2019 Oct; 12(10):. PubMed ID: 31645386
[TBL] [Abstract][Full Text] [Related]
23. Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.
Meers S; Selleslag D; Potier H; Glasmacher A; Mineur P; Voelter V
Curr Med Res Opin; 2015 Jan; 31(1):35-42. PubMed ID: 25317956
[TBL] [Abstract][Full Text] [Related]
24. Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.
Darbaniyan F; Zheng H; Kanagal-Shamanna R; Lockyer P; Montalban-Bravo G; Estecio M; Lu Y; Soltysiak KA; Chien KS; Yang H; Sasaki K; Class C; Ganan-Gomez I; Do KA; Garcia-Manero G; Wei Y
Exp Hematol; 2022 Nov; 115():44-53. PubMed ID: 36150563
[TBL] [Abstract][Full Text] [Related]
25. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
26. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
Wehmeyer J; Zaiss M; Losem C; Schmitz S; Niemeier B; Harde J; Hannig CV; Harich HD; Müller J; Klausmann M; Tessen HW; Potthoff K
Eur J Haematol; 2018 Dec; 101(6):766-773. PubMed ID: 30091166
[TBL] [Abstract][Full Text] [Related]
27. Azacitidine-associated Sweet's syndrome.
Trickett HB; Cumpston A; Craig M
Am J Health Syst Pharm; 2012 May; 69(10):869-71. PubMed ID: 22555082
[TBL] [Abstract][Full Text] [Related]
28. [Systemic and autoimmune manifestations in myelodysplastic syndromes].
Fain O; Braun T; Stirnemann J; Fenaux P
Rev Med Interne; 2011 Sep; 32(9):552-9. PubMed ID: 20850913
[TBL] [Abstract][Full Text] [Related]
29. Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Thota S; Oganesian A; Azab M; Griffiths EA
Future Oncol; 2021 Jun; 17(16):2077-2087. PubMed ID: 33709786
[TBL] [Abstract][Full Text] [Related]
30. Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Saif MW; Hopkins JL; Gore SD
Leuk Lymphoma; 2002 Nov; 43(11):2083-92. PubMed ID: 12533032
[TBL] [Abstract][Full Text] [Related]
31. Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment.
Yi JH; Huh J; Kim HJ; Kim SH; Kim SH; Kim KH; Do YR; Mun YC; Kim H; Kim MK; Kim HJ; Kim T; Kim DD
Ann Hematol; 2013 Apr; 92(4):459-69. PubMed ID: 23262795
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Garcia-Manero G; Gore SD; Cogle C; Ward R; Shi T; Macbeth KJ; Laille E; Giordano H; Sakoian S; Jabbour E; Kantarjian H; Skikne B
J Clin Oncol; 2011 Jun; 29(18):2521-7. PubMed ID: 21576646
[TBL] [Abstract][Full Text] [Related]
33. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
Sekeres MA; Othus M; List AF; Odenike O; Stone RM; Gore SD; Litzow MR; Buckstein R; Fang M; Roulston D; Bloomfield CD; Moseley A; Nazha A; Zhang Y; Velasco MR; Gaur R; Atallah E; Attar EC; Cook EK; Cull AH; Rauh MJ; Appelbaum FR; Erba HP
J Clin Oncol; 2017 Aug; 35(24):2745-2753. PubMed ID: 28486043
[TBL] [Abstract][Full Text] [Related]
34. Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies.
Platzbecker U; Chromik J; Krönke J; Handa H; Strickland S; Miyazaki Y; Wermke M; Sakamoto W; Tachibana Y; Taube T; Germing U
BMC Cancer; 2022 May; 22(1):569. PubMed ID: 35597904
[TBL] [Abstract][Full Text] [Related]
35. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.
Padron E; Steensma DP
Curr Opin Hematol; 2015 Mar; 22(2):163-70. PubMed ID: 25575034
[TBL] [Abstract][Full Text] [Related]
36. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
[TBL] [Abstract][Full Text] [Related]
37. Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry.
Comont T; Heiblig M; Rivière E; Terriou L; Rossignol J; Bouscary D; Rieu V; Le Guenno G; Mathian A; Aouba A; Vinit J; Dion J; Kosmider O; Terrier B; Georgin-Lavialle S; Fenaux P; Mekinian A;
Br J Haematol; 2022 Feb; 196(4):969-974. PubMed ID: 34651299
[TBL] [Abstract][Full Text] [Related]
38. Double minute chromosomes in acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are associated with micronuclei, MYC or MLL amplification, and complex karyotype.
Huh YO; Tang G; Talwalkar SS; Khoury JD; Ohanian M; Bueso-Ramos CE; Abruzzo LV
Cancer Genet; 2016; 209(7-8):313-20. PubMed ID: 27318442
[TBL] [Abstract][Full Text] [Related]
39. LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents.
Chien KS; Class CA; Montalban-Bravo G; Wei Y; Sasaki K; Naqvi K; Ganan-Gomez I; Yang H; Soltysiak KA; Kanagal-Shamanna R; Do KA; Kantarjian HM; Garcia-Manero G
Leuk Lymphoma; 2020 Jun; 61(6):1493-1499. PubMed ID: 32036728
[TBL] [Abstract][Full Text] [Related]
40. Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS syndrome) with prominent supraglottic larynx involvement: a case-based review.
Guerrero-Bermúdez CA; Cardona-Cardona AF; Ariza-Parra EJ; Arostegui JI; Mensa-Vilaro A; Yague J; Vásquez G; Muñoz-Vahos CH
Clin Rheumatol; 2022 Nov; 41(11):3565-3572. PubMed ID: 35986821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
